GeneHealth - Your precision medicine

Molybdenum Cofactor Deficiency

Disease Details

Family Health Simplified

Buy Membership

Description: Molybdenum cofactor deficiency is a rare, autosomal recessive metabolic disorder characterized by the body's inability to synthesize molybdenum cofactor, leading to severe neurological damage and early infantile death.
Type: Molybdenum cofactor deficiency is a metabolic disorder. It is inherited in an autosomal recessive manner.
Signs And Symptoms: **Signs and Symptoms of Molybdenum Cofactor Deficiency:**

- **Neurological Symptoms:** Seizures, hypotonia (reduced muscle tone), and developmental delays.
- **Severe Encephalopathy:** Progressive brain dysfunction leading to severe intellectual disability.
- **Feeding Difficulties:** Due to poor muscle control and neurological impairment.
- **Facial Dysmorphism:** Some patients exhibit distinct facial features like a high forehead and a triangular face.
- **Psychomotor Retardation:** Significant delay in the development of motor skills and cognitive functions.
- **Spasticity:** Increased muscle stiffness and spasms.

The presentation of the disease usually occurs within the first few days to weeks of life, and it is often a rapidly progressive disorder with a poor prognosis.
Prognosis: Molybdenum cofactor deficiency is a rare, genetic metabolic disorder that typically presents in infancy. The prognosis is generally poor. Affected individuals often experience severe neurological symptoms, including seizures, developmental delay, and brain damage. Life expectancy is significantly reduced, with many affected children not surviving beyond early childhood. Currently, no cure exists, but early diagnosis and supportive care may help manage symptoms and improve quality of life.
Onset: Molybdenum cofactor deficiency usually has an onset in the neonatal period or early infancy.
Prevalence: Molybdenum cofactor deficiency is an extremely rare genetic disorder. Its exact prevalence is not well-documented, but it is estimated to occur in fewer than 1 in 100,000 to 200,000 newborns.
Epidemiology: Molybdenum cofactor deficiency is an extremely rare genetic disorder, with an estimated prevalence of less than 1 in 100,000 to 200,000 live births. It is typically diagnosed in infancy. Because it is very rare, precise epidemiological data is limited, and the prevalence may vary by region.
Intractability: Molybdenum cofactor deficiency is generally considered intractable, as there is currently no definitive cure available. The disease is progressive and typically results in significant neurological impairment. Symptomatic treatments and supportive care are often utilized to manage the condition and improve quality of life for affected individuals.
Disease Severity: Molybdenum cofactor deficiency is a rare, severe metabolic disorder. Affected individuals typically present with neurological abnormalities, progressive brain damage, and seizures shortly after birth. Life expectancy is often significantly reduced, with many children not surviving past early infancy.
Healthcare Professionals: Disease Ontology ID - DOID:0111165
Pathophysiology: Molybdenum cofactor deficiency is a rare autosomal recessive metabolic disorder characterized by a deficiency in the activity of molybdoenzymes, particularly sulfite oxidase and xanthine dehydrogenase. The deficiency arises from a disruption in the synthesis of the molybdenum cofactor, which is essential for the proper functioning of these enzymes. Without this cofactor, toxic metabolites such as sulfite accumulate, leading to severe neurological damage, developmental delay, and early infantile death if untreated.
Carrier Status: Molybdenum cofactor deficiency is a rare genetic disorder. The carrier status is typically autosomal recessive, meaning an individual must inherit two copies of the mutated gene, one from each parent, to express the disorder. Carriers, with only one copy of the mutation, usually do not show symptoms. More information might be needed to provide specific details about nan.
Mechanism: Molybdenum cofactor deficiency (MoCD) is a rare genetic disorder characterized by a deficiency of the molybdenum cofactor. This cofactor is essential for the activity of four enzymes: sulfite oxidase, xanthine dehydrogenase, aldehyde oxidase, and mitochondrial amidoxime reducing component (mARC). These enzymes play key roles in metabolic pathways including sulfur-containing amino acids, purine metabolism, and the detoxification processes.

### Mechanism and Molecular Mechanisms:

1. **Genetic Mutations**: MoCD is primarily caused by mutations in one of several genes involved in the biosynthesis of the molybdenum cofactor. These genes include MOCS1, MOCS2, and GPHN. Mutations in these genes disrupt the multi-step process required to synthesize the molybdenum cofactor.

2. **Biosynthesis Pathway**: The biosynthesis of the molybdenum cofactor involves several stages, wherein GTP is converted into molybdopterin. This pathway includes the initial conversion of GTP into cPMP (precursor Z), then to molybdopterin, and finally the incorporation of a molybdenum atom to form the functional molybdenum cofactor.

- **MOCS1 Gene**: Codes for enzymes involved in the initial steps of converting GTP to cPMP.
- **MOCS2 Gene**: This gene encodes for proteins that are critical for the next steps, converting cPMP to molybdopterin.
- **GPHN Gene**: Encodes for gephyrin, necessary for the final step of incorporating molybdenum into molybdopterin.

3. **Enzymatic Defects**: Due to the lack of functional molybdenum cofactor, the aforementioned enzymes (sulfite oxidase, xanthine dehydrogenase, aldehyde oxidase, and mARC) are unable to perform their respective duties. This results in the accumulation of toxic metabolites like sulfites and diminished processes dependent on purine metabolism.

4. **Clinical Manifestations**: Symptoms typically appear in the neonatal period and include severe neurological impairment, feeding difficulties, and seizures. The accumulation of toxic sulfite leads to neurological damage, contributing to these severe clinical features.

Understanding these molecular mechanisms provides insight into the critical functions of the molybdenum cofactor and the wide-ranging effects when it is deficient. Research into potential therapies and interventions is ongoing, focusing on either substituting the deficient molybdenum cofactor or finding ways to bypass the defective biosynthetic pathway.
Treatment: Trials of an experimental treatment are going on at several sites in the US.
https://www.centerwatch.com/clinical-trials/listings/84057/molybdenum-cofactor-deficiency-type-a-study-alxn1101-neonates-molybdenum/
On 26 February 2021, the U.S. Food and Drug Administration approved fosdenopterin (Nulibry) for intravenous injection to reduce the risk of death due to Molybdenum Cofactor Deficiency Type A. Fosdenopterin replaces the missing cyclic pyranopterin monophosphate (cPMP).
Compassionate Use Treatment: Molybdenum cofactor deficiency (MoCD) is a rare genetic disorder that disrupts the body's ability to process certain amino acids, leading to severe neurological damage. There is no established cure, but here are the treatments considered:

1. **Compassionate Use Treatment:**
- **Cyclic Pyranopterin Monophosphate (cPMP, also known as ALXN1101)**: This investigational treatment has been granted compassionate use status in some cases. cPMP is a precursor of the molybdenum cofactor and has been shown to restore the deficient enzyme activity in MoCD Type A.

2. **Off-label or Experimental Treatments:**
- **Liver Transplantation**: Though data are limited, liver transplantation has been considered in some cases to provide the necessary enzymes that the patient's liver is unable to produce.
- **Enzyme Replacement Therapy**: Investigational therapies aim to replace the missing or defective enzymes but are currently in experimental stages.

Patients with MoCD typically need to be managed on a case-by-case basis, often in specialized medical centers.
Lifestyle Recommendations: Molybdenum cofactor deficiency is a rare metabolic disorder that can lead to severe neurological abnormalities and early mortality. While specific lifestyle recommendations for managing this condition are limited due to its rarity and severity, the primary focus is on supportive care and symptom management. Here are general recommendations:

1. **Medical Management:** Work closely with a multidisciplinary medical team to manage symptoms and improve quality of life.
2. **Nutrition:** Provide a balanced diet tailored to the child's needs. Consult a dietitian with experience in metabolic disorders.
3. **Physical Therapy:** Engage in physical therapy to help maintain motor function and prevent contractures.
4. **Occupational Therapy:** Occupational therapy can assist with daily activities and improve quality of life.
5. **Regular Monitoring:** Frequent medical check-ups to monitor the progression of the disease and adjust treatments as necessary.
6. **Support Systems:** Utilize support groups and counseling for emotional and psychological support for both the patient and family members.

Since there is no definitive cure, these recommendations focus on improving the overall quality of life for patients with molybdenum cofactor deficiency.
Medication: Molybdenum cofactor deficiency is a rare genetic disorder typically treated by replacing the missing enzyme. One such medication is cyclic pyranopterin monophosphate (cPMP), which has shown promise in addressing this deficiency. However, treatment options may vary based on individual cases and ongoing research. Consult a specialist for the most current and personalized treatment plan.
Repurposable Drugs: For molybdenum cofactor deficiency, repurposable drugs are highly limited due to the rarity and genetic nature of the disorder. There is no known effective treatment with repurposable drugs as of the latest available information. Management is primarily supportive and aimed at addressing specific symptoms, while research is ongoing to find potential therapies.
Metabolites: Molybdenum cofactor deficiency leads to the accumulation of toxic metabolites such as sulfite, S-sulfocysteine, xanthine, and hypoxanthine due to the dysfunction of molybdenum-dependent enzymes like sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. This metabolic disruption contributes to the severe clinical manifestations of the disorder.
Nutraceuticals: Molybdenum cofactor deficiency is a rare genetic disorder where the body cannot synthesize molybdenum cofactor, leading to a deficiency in the enzymes that require it. This results in severe metabolic dysfunction, primarily affecting the nervous system. There is no established nutraceutical treatment for this condition. Existing treatments focus on symptomatic management and may involve the use of specific enzyme replacement therapy in certain cases. Consulting with a healthcare professional or specialist in metabolic disorders is essential for proper management.
Peptides: Molybdenum cofactor deficiency (MoCD) is a rare autosomal recessive metabolic disorder characterized by a deficiency in the molybdenum cofactor, which is essential for the activity of certain enzymes. The condition affects the sulfite oxidase, causing an accumulation of toxic substances leading to severe neurological damage.

Peptides: While peptides themselves might not directly address MoCD, research into enzyme replacement therapy or gene therapy, which may involve peptide sequences, is ongoing.

Nan: If referring to nanotechnology or nanoparticles, these areas are being explored broadly in medicine but specific nanomedicine treatments for MoCD have not yet been established.

For comprehensive treatment or research information, consult medical resources or professionals.